ES2160239T3 - Composicion farmaceutica filmogena para la administracion transdermica. - Google Patents

Composicion farmaceutica filmogena para la administracion transdermica.

Info

Publication number
ES2160239T3
ES2160239T3 ES96911002T ES96911002T ES2160239T3 ES 2160239 T3 ES2160239 T3 ES 2160239T3 ES 96911002 T ES96911002 T ES 96911002T ES 96911002 T ES96911002 T ES 96911002T ES 2160239 T3 ES2160239 T3 ES 2160239T3
Authority
ES
Spain
Prior art keywords
transdermal administration
pharmaceutical
filmogena
composition
active principle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96911002T
Other languages
English (en)
Other versions
ES2160239T5 (es
Inventor
Henry Saunal
Brigitte Illel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9477595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2160239(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of ES2160239T3 publication Critical patent/ES2160239T3/es
Application granted granted Critical
Publication of ES2160239T5 publication Critical patent/ES2160239T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S602/00—Surgery: splint, brace, or bandage
    • Y10S602/904—Film-forming bandage material

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA LA ADMINISTRACION TRANSDERMICA CARACTERIZADA PORQUE COMPRENDE (A) EVENTUALMENTE UNA MATRIZ POLIMERICA DE LIBERACION, ELEGIDA ENTRE POLIMEROS O COPOLIMEROS CELULOSICOS O COPOLIMEROS VINILPIRROLIDONA/ACETADO DE VINILO, CAPAZ DE FORMAR UNA PELICULA FLEXIBLE DESPUES DEL SECADO; B) UN PRINCIPIO ACTIVO; C) UN PROMOTOR DE LA ABSORCION TRANSCUTANEA DEL PRINCIPIO ACTIVO; (D) UN DISOLVENTE NO ACUOSO FISIOLOGICAMENTE ACEPTABLE CAPAZ DE DISOLVER LA MATRIZ DE LIBERACION, EL PRINCIPIO ACTIVO Y EL PROMOTOR DE ABSORCION TRANSCUTANEA ASI COMO DE ELIMINARLO RAPIDAMENTE POR EVAPORACION EN CONTACTO CON LA PIEL.
ES96911002T 1995-03-30 1996-03-29 Composicion farmaceutica filmogena para la administracion transdermica. Expired - Lifetime ES2160239T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503776A FR2732223B1 (fr) 1995-03-30 1995-03-30 Composition pharmaceutique pour administration transdermique
FR9503776 1995-03-30

Publications (2)

Publication Number Publication Date
ES2160239T3 true ES2160239T3 (es) 2001-11-01
ES2160239T5 ES2160239T5 (es) 2008-05-16

Family

ID=9477595

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96911002T Expired - Lifetime ES2160239T5 (es) 1995-03-30 1996-03-29 Composicion farmaceutica filmogena para la administracion transdermica.

Country Status (33)

Country Link
US (1) US6010716A (es)
EP (1) EP0817621B2 (es)
JP (1) JP3778937B2 (es)
KR (1) KR100260237B1 (es)
CN (1) CN1108790C (es)
AR (1) AR001458A1 (es)
AT (1) ATE202280T1 (es)
AU (1) AU704150B2 (es)
BR (1) BR9607862A (es)
CA (1) CA2214845C (es)
CY (1) CY2280B1 (es)
CZ (1) CZ291914B6 (es)
DE (1) DE69613463T3 (es)
DK (1) DK0817621T4 (es)
EE (1) EE9700241A (es)
ES (1) ES2160239T5 (es)
FR (1) FR2732223B1 (es)
GR (1) GR3036630T3 (es)
HU (1) HU227957B1 (es)
IL (1) IL117728A (es)
IS (1) IS2537B (es)
MX (1) MX9707434A (es)
NO (1) NO323583B1 (es)
NZ (1) NZ305893A (es)
PL (1) PL186004B1 (es)
PT (1) PT817621E (es)
RU (1) RU2161957C2 (es)
SI (1) SI0817621T2 (es)
SK (1) SK282634B6 (es)
TR (1) TR199701083T1 (es)
TW (1) TW442296B (es)
WO (1) WO1996030000A1 (es)
ZA (1) ZA962536B (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4241706C2 (de) * 1992-12-10 1997-03-20 Ahlmann Aco Severin Befestigungseinrichtung für die Abdeckung einer Oberflächenentwässerungseinrichtung
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6998138B2 (en) 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6916486B2 (en) 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US7094422B2 (en) 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6916487B2 (en) 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
DE19616539A1 (de) * 1996-04-25 1997-11-06 Luitpold Pharma Gmbh Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
DE19742275A1 (de) * 1997-09-25 1999-04-01 Beiersdorf Ag Estern verzweigtkettiger Carbonsäuren und verzweigtkettiger Alkohole als antibakterielle, antimycotische, antiparasitäre oder antivirale Wirkstoffe
NZ509618A (en) 1998-08-20 2003-09-26 3M Innovative Properties Co A patch-in-a-bottle that provides a fluid composition, which is applied to a surface and subsequently dries to form a covering, such as a patch
US6503488B1 (en) * 1998-11-17 2003-01-07 Tend Skin International, Inc. Topical compositions including deodorant compositions
FR2787712B1 (fr) * 1998-12-24 2002-08-30 Sanofi Sa Composition cosmetique pulverisable et matrice utilisable dans cette composition pour une administration dermique
RO121628B1 (ro) * 1999-02-05 2008-01-30 Cipla Limited Compoziţie medicinală, topică, pulverizabilă,dozator care o conţine, procedeu de realizare a dozatorului şi utilizarea compoziţiei menţionate
AU4543200A (en) * 1999-04-16 2000-11-02 Dittgen, Michael Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
AUPQ419099A0 (en) * 1999-11-23 1999-12-16 Ko, Thomas Sai Ying Novel compositions and methods
DE10019311A1 (de) * 2000-04-19 2001-10-31 Lohmann Therapie Syst Lts Transdermale therapuetische Systeme zur Applikation von Moxonidin
FR2808685B1 (fr) * 2000-05-12 2004-10-08 Sanofi Synthelabo Compositions pharmaceutiques pour administration transdermique d'agents anti-inflammatoires
DE10025971B4 (de) * 2000-05-25 2004-09-02 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE10110391A1 (de) * 2001-03-03 2002-09-26 Lohmann Therapie Syst Lts Hochflexibles Nikotin transdermales therapeutisches System mit Nikotin als Wirkstoff
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
EP1344522A1 (en) * 2001-05-08 2003-09-17 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
WO2002092616A1 (en) * 2001-05-11 2002-11-21 Orasense, Ltd. Antisense permeation enhancers
RU2211213C2 (ru) * 2001-05-16 2003-08-27 Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории" Лекарственное средство, обладающее противоязвенным, кардиопротективным и противошоковым действием
NZ530278A (en) * 2001-06-01 2006-06-30 Tendskin Company Topical composition containing a salicylate derivative for veterinary use in treating dermatological disorders
MXPA04003266A (es) * 2001-10-05 2004-07-08 Combinatorx Inc Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios.
US20030118655A1 (en) * 2001-12-21 2003-06-26 Nikhil Kundel Film forming liquid composition
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
CA2489865C (en) 2002-06-25 2012-05-08 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
AU2003242346A1 (en) * 2002-06-27 2004-01-19 Pola Chemical Industries Inc. Drug composition
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
EP1426049B1 (en) * 2002-12-02 2005-05-18 Schwarz Pharma Ag Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
JO2492B1 (en) 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
US20040265364A1 (en) * 2003-06-25 2004-12-30 Binnur Ozturk Neuropathy cream
US20050095277A1 (en) * 2003-06-25 2005-05-05 Binnur Ozturk Neuropathy cream
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP2007509122A (ja) * 2003-10-23 2007-04-12 シプラ・リミテッド Ｖｐ／ｖａ共重合体及び非水性ビヒクルを含有する、経皮的医薬スプレー製剤
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
JP5208507B2 (ja) * 2004-09-23 2013-06-12 ダウ グローバル テクノロジーズ エルエルシー 粘膜又は皮膚医療又は衛生処理システム
JP5117196B2 (ja) * 2005-01-04 2013-01-09 テイコク ファーマ ユーエスエー インコーポレーテッド 冷却局所用貼付製剤
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
MX2007013708A (es) * 2005-05-03 2008-01-28 Innozen Inc Pelicula comestible para suministro transmucosa de complementos nutricionales.
KR20130114229A (ko) * 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
DK2450041T3 (en) 2005-10-12 2018-11-19 Unimed Pharmaceuticals Llc Enhanced testosterone gel for use in the treatment of hypogonadism
US20070258935A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water dispersible films for delivery of active agents to the epidermis
US20070259029A1 (en) * 2006-05-08 2007-11-08 Mcentire Edward Enns Water-dispersible patch containing an active agent for dermal delivery
CA2652773A1 (en) * 2006-05-22 2007-12-06 Combinatorx, Incorporated Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels
US20080057090A1 (en) * 2006-09-01 2008-03-06 Mcentire Edward Enns Wrinkle masking film composition for skin
US7879942B2 (en) * 2006-10-05 2011-02-01 Eastman Chemical Company Switchable adhesive article for attachment to skin and method of using the same
CA2674661C (en) 2007-01-11 2016-10-11 Acrux Dds Pty Ltd Spreading implement
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CA2737131A1 (en) * 2007-09-19 2009-03-26 Zalicus Inc. Therapeutic regimens for the treatment of immunoinflammatory disorders
JP2011506607A (ja) * 2007-12-17 2011-03-03 ザリカス インコーポレイティッド 免疫炎症性障害の処置のための治療法
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
JP5966261B2 (ja) * 2010-06-17 2016-08-10 大正製薬株式会社 外用組成物
CN102309447A (zh) * 2010-07-06 2012-01-11 上海现代药物制剂工程研究中心有限公司 含盐酸奥昔布宁的自粘性喷雾透皮组合物及制备方法
CA2719512A1 (en) 2010-11-01 2012-05-01 Stiefel Research Australia Pty Ltd Polymeric topical compositions
WO2013054809A1 (ja) * 2011-10-14 2013-04-18 大正製薬株式会社 皮膚外用剤
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
JP2013147442A (ja) * 2012-01-18 2013-08-01 Kose Corp グリチルレチン酸ステアリルの皮膚浸透促進剤
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
RU2534521C2 (ru) * 2012-11-27 2014-11-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Национальный исследовательский Томский государственный университет" (ТГУ) Способ трансдермального введения инсулина и устройство для его осуществления
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
DE102017104026A1 (de) * 2017-02-27 2018-08-30 Lts Lohmann Therapie-Systeme Ag Nicotin enthaltendes transparentes transdermales therapeutisches System
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
WO2019140087A1 (en) * 2018-01-10 2019-07-18 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
CN109394735B (zh) * 2018-11-09 2022-01-28 北京德默高科医药技术有限公司 具有高溶解度的布洛芬或其结构类似物经皮给药系统
JP2021006522A (ja) * 2019-06-27 2021-01-21 ロート製薬株式会社 被膜形成性皮膚外用組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045915A1 (de) * 1980-12-05 1982-07-08 Bayer Ag, 5090 Leverkusen Antimykotische mittel mit hoher wirkstoff-freisetzung in form von elastischen fluessig-pflastern
DE3045914A1 (de) * 1980-12-05 1982-07-22 Bayer Ag, 5090 Leverkusen Antimykotische mittel mit hoher wirkstoff-freisetzung in form von elastischen fluessig-pflastern
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
FR2612785A1 (fr) * 1987-03-25 1988-09-30 Lhd Lab Hygiene Dietetique Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee
EP0289900A1 (en) * 1987-04-30 1988-11-09 Abbott Laboratories Topical antibacterial compositions
DE3868248D1 (de) * 1987-05-27 1992-03-12 Burghart Kurt Transdermal therapeutisch wirkende pharmazeutische zubereitung sowie vorrichtung zum aufbringen der zubereitung.
JPH07116035B2 (ja) * 1987-12-08 1995-12-13 塩野義製薬株式会社 被膜形成性抗真菌剤組成物
FR2635979B1 (fr) * 1988-09-07 1992-05-29 Lhd Lab Hygiene Dietetique Dispositif auto-adhesif d'administration d'un principe actif par voie percutanee
WO1994013257A1 (en) * 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
US5547662A (en) * 1993-08-27 1996-08-20 Becton, Dickinson And Company Preparation of a skin surface for a surgical procedure
KR960011044B1 (ko) * 1993-09-27 1996-08-16 재단법인 한국화학연구소 알칸올 투과가 우수한 고분자막

Also Published As

Publication number Publication date
EE9700241A (et) 1998-04-15
AU5402296A (en) 1996-10-16
IL117728A (en) 1999-08-17
CN1108790C (zh) 2003-05-21
CZ308197A3 (cs) 1998-04-15
FR2732223B1 (fr) 1997-06-13
EP0817621B2 (fr) 2007-12-26
EP0817621A1 (fr) 1998-01-14
PL186004B1 (pl) 2003-09-30
HUP9904174A3 (en) 2000-06-28
US6010716A (en) 2000-01-04
JP3778937B2 (ja) 2006-05-24
IS4566A (is) 1997-09-22
AU704150B2 (en) 1999-04-15
GR3036630T3 (en) 2001-12-31
BR9607862A (pt) 1998-06-30
NO974507D0 (no) 1997-09-29
EP0817621B1 (fr) 2001-06-20
ES2160239T5 (es) 2008-05-16
SI0817621T2 (sl) 2008-06-30
CY2280B1 (en) 2003-07-04
KR100260237B1 (ko) 2000-08-01
NZ305893A (en) 1999-11-29
DE69613463T3 (de) 2008-07-24
IS2537B (is) 2009-08-15
CA2214845C (fr) 2003-01-07
SK282634B6 (sk) 2002-10-08
CA2214845A1 (fr) 1996-10-03
JPH11502828A (ja) 1999-03-09
SI0817621T1 (en) 2001-12-31
PT817621E (pt) 2001-11-30
CN1182365A (zh) 1998-05-20
HU227957B1 (en) 2012-07-30
NO974507L (no) 1997-09-29
CZ291914B6 (cs) 2003-06-18
TR199701083T1 (xx) 1998-02-21
KR19980703624A (ko) 1998-12-05
WO1996030000A1 (fr) 1996-10-03
DK0817621T4 (da) 2008-04-28
ZA962536B (en) 1997-09-29
HUP9904174A2 (hu) 2000-04-28
ATE202280T1 (de) 2001-07-15
DE69613463T2 (de) 2002-06-06
MX9707434A (es) 1997-12-31
RU2161957C2 (ru) 2001-01-20
FR2732223A1 (fr) 1996-10-04
SK130697A3 (en) 1998-06-03
DE69613463D1 (de) 2001-07-26
AR001458A1 (es) 1997-10-22
TW442296B (en) 2001-06-23
PL322502A1 (en) 1998-02-02
IL117728A0 (en) 1996-07-23
DK0817621T3 (da) 2001-09-24
NO323583B1 (no) 2007-06-11

Similar Documents

Publication Publication Date Title
ES2160239T3 (es) Composicion farmaceutica filmogena para la administracion transdermica.
ES2159591T3 (es) Composicion de liberacion controlada.
MXPA96004911A (es) Pellas de matriz de liberacion lenta y su produccion.
AR023549A1 (es) Sistema terapeutico transdermal con adhesivos de contacto de acrilato neutralizados
CL2004000674A1 (es) Sistema terapeutico transdermico que comprende al menos una sustancia activa farmaceutica, al menos un disruptor de la estructura y/o al menos un formador de estructura en una matriz comun.
UY26391A1 (es) Inhibidores sglt2 de glucosidos de c-arilo y metodo
AR023715A1 (es) Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel
ES2160623T3 (es) Composiciones farmaceuticas mejoradas para la penetracion en la piel de piroxicam.
ES2096103T3 (es) Preparacion de comprimidos de resistencia incrementada.
AR018286A1 (es) Composicion farmaceutica que en calidad de principio activo contiene la asociacion de metformina y fibrato, y la utilizacion de esta asociacion para preparar medicamentos
CO4290295A1 (es) Medicamento en forma de comprimido con liberacion retardada de sustancia activa
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
AR015360A1 (es) Proceso para la manufactura de una composicion farmaceutica para reducir o prevenir los efectos de la inflamacion; dicha composicion farmaceutica y unelemento para aplicar la composicion farmaceutica en dicho proceso
ES2133000T3 (es) Composicion cosmetica y/o dermatologica que contiene al menos un precursor de agente activo y un poli(acido 2-acrilamido 2-metilpropano sulfonico) reticulado.
WO2001085143A3 (fr) Compositions pharmaceutiques pour administration transdermique d' agents anti-inflammatoires
BRPI0412211A (pt) composições de liberação controlada
BR0012696A (pt) Composição oftálmica
AR032872A1 (es) Composicion para aclarar la piel y el metodo de aplicacion
PT1079839E (pt) Agente terapeutico contra constipacoes contendo a isomaltose como principio activo
ES2142388T3 (es) Agente anti-diabetico.
CO6270206A2 (es) Producto de dispersion solida de drogas basadas en n-aril urea
PE17897A1 (es) Formulacion transdermica en parche del 3-(4-butiltio)-1,2,5-tiadiazol-3-il)-1-azabiciclo (2,2,2) octano
MX9304459A (es) Material polihidroxilico de enlace curzado para la liberacion de farmacos controlada por enzimas.
CO5540370A2 (es) Comprimido que comprende cetirizina y pseudoefredina
AR246159A1 (es) Agente antiparasitario con accion mejorada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 817621

Country of ref document: ES